Abivax ADR [ABVX] stock is trading at $68.96, down -1.50%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ABVX shares have lost -4.10% over the last week, with a monthly amount glided 580.08%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Abivax ADR [NASDAQ: ABVX] stock has seen the most recent analyst activity on July 23, 2025, when Morgan Stanley upgraded its rating to a Overweight but kept the price target unchanged to $71 for it. Previously, Morgan Stanley started tracking the stock with Equal-Weight rating on March 20, 2025, and set its price target to $12. On December 04, 2024, JMP Securities initiated with a Mkt Outperform rating and assigned a price target of $33 on the stock. Laidlaw started tracking the stock assigning a Buy rating and suggested a price target of $48 on July 29, 2024. BTIG Research initiated its recommendation with a Buy and recommended $43 as its price target on May 20, 2024. Piper Sandler started tracking with a Overweight rating for this stock on April 29, 2024, and assigned it a price target of $42. In a note dated April 29, 2024, Guggenheim initiated a Buy rating and provided a target price of $50 on this stock.
Abivax ADR [ABVX] stock has fluctuated between $4.77 and $75.51 over the past year. Currently, Wall Street analysts expect the stock to reach $39.67 within the next 12 months. Abivax ADR [NASDAQ: ABVX] shares were valued at $68.96 at the most recent close of the market. An investor can expect a potential drop of -42.47% based on the average ABVX price forecast.
Analyzing the ABVX fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -17.18%, Pretax Profit Margin comes in at -16.95%, and Net Profit Margin reading is -16.33%. To continue investigating profitability, this company’s Return on Assets is posted at -0.86, Equity is -2.11 and Total Capital is -1.67. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.4.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 68.39 points at the first support level, and at 67.81 for the second support level. However, for the 1st resistance point, the stock is sitting at 69.55, and for the 2nd resistance point, it is at 70.13.
Ratios To Look Out For
For context, Abivax ADR’s Current Ratio is 1.25. In addition, the Quick Ratio stands at 1.25 and the Cash Ratio stands at 1.53.
